Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure

Launched by UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTRE · Jun 24, 2022

Keywords

ClinConnect Summary

i. To determine the abv3-integrin expression isolated from endometrium tissue from women with RIF prior to medical therapy.

ii. To determine the abv3-integrin expression isolated from endometrium tissue from Group A, Group B and Group C following the medical therapy.

iii. To compare the abv3-integrin expression from endometrium tissue obtained from Group A, B and C following the medical therapy.

iv. To compare the implantation rates among Group A, B and C following the medical therapy.

v. To compare the ongoing pregnancy among Group A, B and C following the medical therapy

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women of 18 to 40 years of age
• • No significant pre-existing major medical.
• • Diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (ET) despite the optimum endometrial thickness and good quality of embryo (unexplained).
• • Regular menstrual cycle atleast 3 months prior to treatment
• • Not taking any hormonal treatment for atlest 3months prior to recruitment
• • Agreed to participate
• Exclusion Criteria:
• • Concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (SLE) or Anti Phospholipid Syndrome (APS) that will interfere with implantation.
• • Poor quality of embryo
• • Suboptimal endometrial thickness(\<8mm) during the embryo transfer (ET).
• • On hormonal therapy prior to recruitment.
• • Not agreed to participate